Medicine Press release

Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI(R)), our anti-amyloid beta (AB) protofibril antibody for the treatment of Alzheimer's disease (AD) and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference(R) 2026 (AAIC(R)) from July 12-15 in London and online.
More info..

Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI(R)), our anti-amyloid beta (AB) protofibril antibody for the treatment of Alzheimer's disease (AD) and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference(R) 2026 (AAIC(R)) from July 12-15 in London and online.
More info..

Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI(R)), our anti-amyloid beta (AB) protofibril antibody for the treatment of Alzheimer's disease (AD) and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference(R) 2026 (AAIC(R)) from July 12-15 in London and online.
More info..

University College London (UCL) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) have signed a new agreement to extend their long-standing collaboration in drug discovery and development for five more years, taking the partnership through to 2030.
More info..

University College London (UCL) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) have signed a new agreement to extend their long-standing collaboration in drug discovery and development for five more years, taking the partnership through to 2030.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.
More info..